- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02211105
Registry to Compare Two Surgical Treatments for GERD (STAR Registry)
Laparoscopic Nissen Fundoplication (LNF) Surgery Versus Transoral Incisionless Fundoplication (TIF): Anti- Reflux Treatment Registry
Study Overview
Status
Conditions
Detailed Description
This registry will prospectively enroll 500 patients undergoing TIF and LNF from approximately 20 United States centers proficient in these procedures that have provided informed consent for the above mentioned data collection (symptom questionnaires, medical treatments, complications, side-effects and costs). The observational registry will obtain the patients clinical data related to gastrointestinal symptoms for three years post-consent.
At baseline and for a three-year period following a clinically indicated TIF or LNF procedure, data will be obtained from phone calls and/or during office-visits made at specified intervals. During these data collection periods, patients will be asked to complete standard validated symptom questionnaires as well as report on episodes of care related to their procedures along with financial costs of care.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Huntington Beach, California, United States
- OC Reflux
-
-
Colorado
-
Englewood, Colorado, United States, 80110
- SurgOne Foregut Institute
-
-
Illinois
-
Chicago, Illinois, United States
- GI Solutions Inc
-
Evanston, Illinois, United States, 60201
- NorthShore University HealthSystem
-
-
New York
-
New York, New York, United States, 10011
- Lenox Hill Hospital
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Oregon Health & Science University
-
-
Texas
-
Bellaire, Texas, United States, 77401
- University of Texas at Houston
-
El Paso, Texas, United States, 79912
- Texas Tech University Health Sciences Center
-
-
Virginia
-
Reston, Virginia, United States, 20190
- Reston Hospital Center/ GW University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- GERD symptoms (heartburn, defined by a sub-sternal burning discomfort arising from the upper abdomen into the chest, and or regurgitation, defined as the effortless arising of liquid material into the chest or mouth) two or more times a week (when not on anti-secretory medication) that adversely affects the patient's quality of life. Additionally, patients will have to have responded to medical therapy (adequate relief of symptoms) as indicated by GERD-HRQL and regurgitation scores on medical therapy. In this context, scores ≤ 2 on each GERD-HRQL and regurgitation question (while on medication) indicate absence of daily bothersome symptoms and therefore these patients are considered responsive to medical therapy. Furthermore, patients will have to have objective evidence of GERD documented (esophagitis on endoscopy or pathological intraesophageal acid exposure on prolonged ambulatory esophageal pH monitoring).
- Age 18-80 years
- Ability to give informed consent
- Regular access to a telephone
Meet the clinical criteria for treatment of GERD with TIF or LNF and undergo TIF or LNF within 90 days of providing consent.
- Dependent upon PPIs for control of heartburn for > six months or patient determined to have an inadequate response of regurgitation symptoms despite heartburn control with PPIs
- Hiatal hernia axial length is no larger than 2 cm and the transverse dimension should not exceed 2.0 cm
Gastroesophageal junction with a Hill Grade I-II
--- Patient willing to provide informed consent, cooperate with post-operative dietary recommendations and follow-up assessment tests
- Objective documentation of pathological acid-reflux by either a) increased intraesophageal acid exposure on prolonged ambulatory esophageal pH monitoring (pH<4 for 4.5% or greater of the time) with or without impedance b) or the presence of erosive esophagitis (LA Grade A or B) on endoscopy
- Absence of a severe esophageal motility disorder (note: mild abnormalities in esophageal motility are common in GERD such as small breaks, etc.) including achalasia, esophagogastric junction outflow obstruction, frequent failed peristalsis, diffuse esophageal spasm, nutcracker or jackhammer esophagus etc. on high-resolution esophageal manometry using the Chicago classification system or evidence of incomplete bolus clearance on 30% or more of swallows by impedance testing.
Exclusion Criteria:
- Hiatal hernia > 2 cm (defined as longitudinal length measured endoscopically between the proximal margin of the gastric folds and the diaphragmatic pinch)
- Esophagitis LA Grade C or D
- Presence of troublesome atypical symptoms
- Barrett's esophagus greater than 2 cm in length or with any dysplasia
- Esophageal stricture or severe esophageal motility disorder
History of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, cirrhosis or any other uncontrolled systemic disease
--. Active gastro-duodenal ulcer disease
- Gastric outlet obstruction or stenosis
- Gastroparesis or delayed gastric emptying confirmed by a four hour solid-phase gastric emptying study
- Body Mass Index (BMI) > 35
- Pregnancy or plans for pregnancy within 12 months of the procedure
- Portal hypertension and/or varices
- New York Heart Association classification of III or IV.
- Coagulation disorders
- Intraprocedural determination of anatomical presentation which in the opinion of the surgeon does not allow safe performance of the procedure
- Enrollment in another device or drug study that may confound result
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Laparoscopic Nissen Fundoplication
Patients whose GERD is being treated surgically through Laparoscopic Nissen Fundoplication.
|
Transoral Incisionless Fundoplication
Patients whose GERD is being treated surgically through Transoral Incisionless Fundoplication.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness as measured by a 75% reduction in GERD HRQL)
Time Frame: 3 years
|
To compare the effectiveness of TIF and LNF at the end of three years compared to baseline using a 75% reduction in GERD Health-related Quality of Life (GERD-HRQL) as a threshold for effectiveness.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness using a 50% reduction in GERD-HRQL
Time Frame: 3 years
|
Compare effectiveness using a 50% reduction in GERD-HRQL as a threshold for effectiveness of TIF and LNF at the end of three years compared to baseline.
|
3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Durability of GERD surgeries
Time Frame: 1 year and 3 years
|
Compare the durability of TIF to LNF by determining the proportion of patients that achieve either a) >75% or b) >50% within the first year that maintain this effect at three years
|
1 year and 3 years
|
Comparison of TIF to LNF for Patient reported symptoms
Time Frame: 3 years
|
Compare TIF to LNF with respect to other reported GI symptoms, complications and side effects.
|
3 years
|
Comparison of Post-Procedure cost
Time Frame: 3 years
|
Estimate the post-procedure costs associated with episodes of care and any ensuing complications or side effects of TIF and LNF.
|
3 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: M. Brian Fennerty, M.D., Oregon Health and Science University
- Principal Investigator: W. Scott Melvin, M.D., Montefiore Medical Center
- Study Chair: Ashish Atreja, M.D., Mount Sinai Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AGA STAR Registry
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GastroEsophageal Reflux Disease
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
King Chulalongkorn Memorial HospitalCompleted
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
PfizerTerminatedGastroesophageal Reflux DiseaseBrazil, Germany, Korea, Republic of, Belgium, Spain, Slovakia, France
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux Disease (GERD) | RefluxUnited States, Canada